Stock CGEN COMPUGEN LTD.
Add to a list
To use this feature you must be a member
Log inSign up

News Compugen Ltd.

Equities

CGEN

IL0010852080

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-24 pm EDT 		5-day change 1st Jan Change
2.44 USD +7.49% Intraday chart for Compugen Ltd. +15.64% +23.23%
May. 20 Truist Securities Trims Price Target on Compugen to $4 From $5, Maintains Buy Rating MT
May. 20 Transcript : Compugen Ltd., Q1 2024 Earnings Call, May 20, 2024

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Truist Securities Trims Price Target on Compugen to $4 From $5, Maintains Buy Rating
MT
Compugen : Reports First Quarter 2024 Results
PU
Transcript : Compugen Ltd., Q1 2024 Earnings Call, May 20, 2024
Earnings Flash (CGEN) COMPUGEN Reports Q1 Revenue $2.6M, vs. Street Est of $1.2M
MT
Compugen: Q1 Earnings Snapshot
AQ
Compugen Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Compugen Reports First Quarter 2024 Results
PR
Compugen : Publishes Paper in Cancer Immunology Research on Unique Biology of PVRIG and its Therapeutic Potential
PU
Compugen Names David Silberman CFO
MT
Compugen Appoints David Silberman as Chief Financial Officer
PR
Compugen Ltd. Announces CFO Changes, Effective August 15, 2024
CI
Compugen to Release First Quarter 2024 Results on Monday, May 20, 2024
PR
Compugen to Present New Clinical Data Showing COM701 Triple Combination Preliminary Anti-Tumor Activity in Microsatellite Stable Colorectal Cancer with Liver Metastases at ASCO 2024
AQ
Compugen : To Present New Clinical Data Showing COM701 Triple Combination Preliminary Anti-Tumor Activity in Microsatellite Stable Colorectal Cancer with Liver Metastases at ASCO 2024
PU
Compugen to Participate in Two Upcoming Investor Conferences
PR
Compugen : Selected for two Oral Presentations at the Keystone Symposium on Cancer Immunotherapy
PU
Compugen Selected for two Oral Presentations at the Keystone Symposium on Cancer Immunotherapy
PR
Truist Securities Adjusts Price Target on Compugen to $5 From $4, Maintains Buy Rating
MT
Compugen to Present Data Reflecting its Diversified Immuno-Oncology Pipeline at AACR 2024
AQ
Compugen : To Present Data Reflecting its Diversified Immuno-Oncology Pipeline at AACR 2024
PU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CGEN Stock
  4. News Compugen Ltd.